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Abstract
The beneficial effects of total parenteral nutrition (TPN) in improving the nutritional status of malnourished patients during hospital stays have
been well established. However, recent randomized trials and meta-analyses have reported an increased rate of TPN-associated complications and 
mortality in critically ill patients. The increased risk of complications during TPN therapy has been linked to the development of hyperglycemia, 
especially during the first few days of TPN therapy. This retrospective study was conducted to determine whether the amount of dextrose from
TPN in the 1
st week in the intensive care unit (ICU) was related to the development of hyperglycemia and the clinical outcome. We included 
88 non-diabetic critically ill patients who stayed in the medical ICU for more than two days. The subjects were 65 ± 16 years old, and the mean
APACHE (Acute Physiology and Chronic Health Evaluation) Ⅱ score upon admission was 20.9 ± 7.1. The subjects received 2.3 ± 1.4 g/kg/day 
of dextrose intravenously. We divided the subjects into two groups according to the mean blood glucose (BG) level during the 1
st w e e k  o f IC U
stay: < 140 mg/dl vs ≥140 mg/dl. Baseline BG and the amount of dextrose delivered via TPN were significantly higher in the hyperglycemia
group than those in the normoglycemia group. Mortality was higher in the hyperglycemia group than in the normoglycemia group (42.4% vs 12.8%,
P= 0.008). The amount of dextrose from TPN was the only significant variable in the multiple linear regression analysis, which included age, APACHE
Ⅱ score, baseline blood glucose concentration and dextrose delivery via TPN as independent variables. We concluded that the amount of dextrose
delivered via TPN might be associated with the development of hyperglycemia in critically ill patients without a history of diabetes mellitus. The
amount of dextrose in TPN should be decided and adapted carefully to maintain blood glucose within the target range.
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Introduction11)
Parenteral nutrition (PN) is an important means of providing 
nutrition to patients with a nonfunctional gastrointestinal tract, 
limited absorptive capacity, or other problems that prevent enteral 
feeding. Although PN has improved patient outcomes, recent 
randomized trials and meta-analyses have raised questions about 
its safety and the high rate of total parenteral nutrition (TPN)- 
associated complications and mortality in critically ill patients 
[1,2]. The current clinical guidelines for nutritional support in 
critically ill patients differ substantially by society. The 
Guidelines for the Nutrition Support Therapy in Critically Ill 
Patient by the American Society of Parenteral and Enteral 
Nutrition (ASPEN) and the Society of Critical Care Medicine 
(SCCM) [3] recommend early initiation of enteral nutrition but 
suggest that PN therapy be initiated after seven days for critically 
ill patients who are well nourished at baseline. In contrast, the 
guidelines of the European Society of Parenteral and Enteral 
Nutrition (ESPEN) recommended that practitioners consider 
initiating parenteral nutrition within two days of admission to 
the intensive care unit (ICU) for patients who cannot be adequately 
fed enterally [4].
The increased risk of TPN-associated complications can be 
related, among other factors, to the development of hyperglycemia 
[5,6]. TPN might cause hyperglycemia in patients with no history 
of diabetes mellitus [7]; hyperglycemia during TPN therapy can 
cause a higher mortality rate and prevalence of complications, 
especially infectious complications. However, there have been 
few studies to evaluate the effects of the amount of dextrose 
from TPN on the development of hyperglycemia. Therefore, we 
conducted this study to examine whether the amount of dextrose 
from TPN was associated with hyperglycemia and how it affects 
clinical outcomes in critically ill patients with no history of 
diabetes mellitus. 
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All
(n = 88)
Normoglycemia
(n = 29)
Hyperglycemia
(n = 59) P-value
Age (yr) 65 ± 16 63.8 ± 17.5 64.9 ± 17.1 0.772
Gender (M:F) 49:39 16:13 33:26 1.000
APACHEⅡ 20.9 ± 7.1 19.4 ± 7.6 21.8 ± 6.7 0.192
ICU stay (days) 21.8 ± 22.2 24.0 ± 28.4 20.8 ± 18.6 0.959
Duration of MV (days) 18.7 ± 19.8 20.5 ± 25.4 17.8 ± 16.7 0.999
Complications (%) 27 (30.7) 9 (31.0) 18 (30.5) 1.000
Infectious (%) 15 (17.0) 5 (17.2) 10 (16.9) 0.680
Renal (%) 16 (18.2) 3 (10.3) 13 (22.0) 0.245
Cardiac (%) 4 (4.5) 2 (6.9) 2 (3.4) 0.596
Mortality (%) 29 (33.0) 4 (13.8) 25 (42.4) 0.008
We divided the subjects into two groups according to the mean blood glucose level 
during the first week of ICU care:  < 140  mg/dl,  normoglycemia  group  vs  ≥ 140 
mg/dl,  hyperglycemia  group. 
M:F, male:female; APACHE, Acute physiology and chronic health evaluation; ICU, 
Intensive  care  unit;  MV,  Mechanical  ventilation 
Table 1. General characteristics of the normoglycemia and hyperglycemia 
groups
Subjects and Methods
Subjects 
Between January 2009 and December 2009, 160 critically ill 
adult patients were admitted to the medical intensive care unit 
(ICU) of Severance Hospital, affiliated with Yonsei University 
College of Medicine in Seoul, Korea, where they stayed for more 
than two days. We analyzed the data of 88 patients after 
excluding 72 patients with a history of diagnosis and management 
of diabetes mellitus before ICU admission or treatment with 
steroid therapy during ICU care. We divided the subjects into 
two groups according to their mean blood glucose levels during 
the first week of ICU care: < 140 mg/dl as the normoglycemia 
group vs ≥140 mg/dl as the hyperglycemia group. The Institutional 
Review Board waived informed consent because this study was 
a retrospective chart review.
Methods
We retrospectively collected the patient data from the electric 
medical record. We recorded patients’ general characteristics 
including age, gender, diagnosis, department of primary physician, 
Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE 
Ⅱ) score, length of stay and mortality in the ICU. We also 
collected data on TPN order and nutrition delivery, including 
the day of TPN initiation after ICU admission and carbohydrate 
delivery from TPN and enteral nutrition (EN), daily mean blood 
glucose (BG) level, and the insulin infusion rate during the first 
week in the ICU. Dextrose provided via the intravascular route 
included the total dextrose from TPN solution and 10% dextrose 
in water (D/W) solution, 20% D/W and 50% D/W solution 
(Choongwae Pharma Corp., Korea).
In our ICU, blood glucose levels were measured four times 
a day, every 6 hours. If the patients’ BG level was measured 
at > 200 mg/dl twice, insulin infusion was started and BG level 
monitored every 2 hours until it reached the target range between 
100 mg/dl and 140 mg/dl. We recorded four measurements of 
BG daily, even when the titration of insulin dose was checked 
more than four times. In the ICU, capillary blood glucose levels 
were measured using Accu-Chek Comfort Curative test strips 
(Roche Diagnostics GmbH, Germany) and a glucometer (Accu- 
Chek
® Inform system, Roche Diagnostics GmbH, Germany).
Newly developed complications such as infection, acute renal 
failure and cardiac complications were recorded to analyze the 
relationship between hyperglycemia and the prevalence of 
complications. Infectious complications included infection of the 
urinary tract, respiratory system and bloodstream. Acute renal 
failure was defined as newly diagnosed renal failure requiring 
continuous renal replacement therapy in the ICU. Cardiac 
complications included myocardial infarction, arrhythmia and 
cardiogenic arrest.
Statistical analysis
All results were expressed as mean ± SD. We compared the 
two groups according to blood glucose level, using the chi-square 
test for categorical data and the student’s t-test for continuous 
data after normalizing the variables that did not follow normal 
distribution: length of stay in ICU, duration of mechanical 
ventilation, overfeeding days during transitional feeding from 
TPN to EN, number of days of insulin use and carbohydrate 
delivery from EN. Multivariate analysis was conducted with 
stepwise multiple linear regression analysis. P< 0.05 was considered 
significant. Data were analyzed with PASW Statistics 18.0- 
August 2009 (SPSS in IBM, Armonk, NY).
Results
General characteristics
The general characteristics of the subjects are shown in Table 
1. The subjects were 65 ± 16 years old, and 49 patients (55.7%) 
were male. APACHE Ⅱ score within 24 hr after ICU admission 
was 20.9 ± 7.1. Length of stay in the ICU was 21.8 ± 22.2 days, 
and mortality in the ICU was 33%.
TPN was initiated 1.2 ± 0.6 days after ICU admission and 
provided for 14.4 ± 12.5 days. Five patients were not provided 
with TPN during their ICU stay, and TPN was not ordered for 
six patients during the first week of ICU stay. Average dextrose 
delivery from TPN and IV solution was 2.3 ± 1.4 g/kg/day. EN 
was provided to 75 patients within the first week of ICU 
admission and to 61 patients within three days of ICU admission. 
More calories than the estimated requirement were provided to 
36 patients for 6.2 ± 6.0 days during the transitional process from 
TPN to EN.452 TPN dextrose and hyperglycemia in the ICU
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Fig. 1. Amount of carbohydrate delivery via TPN and EN. We  divided  the 
subjects into two groups according to the mean blood glucose level during the first 
week  of  ICU  care:  < 140  mg/dl,  normoglycemia  group  vs  ≥ 140  mg/dl, 
hyperglycemia  group.  TPN,  total  parenteral  nutrition;  EN,  enteral  nutrition
Normogylcemia
(n = 29)
Hyperglycemia
(n = 59) P-value
TPN order
Time to TPN start from ICU 
admission (days)
1.3 ± 0.5 1.7 ± 1.3 0.261
Duration of TPN use (days) 15.0 ± 14.0 14.1 ± 11.9 0.764
Duration of overfeeding when 
transitioning from TPN to EN 
(days)
8.2 ± 9.5 5.1 ± 4.9 0.197
Baseline blood glucose (mg/dl) 131.9 ± 35.6 168.4 ± 65.1 0.001
Average BG concentration during 
the first week of ICU stay (mg/dl)
122.9 ± 13.4 175.7 ± 31.3 < 0.0001
Frequency of hyperglycemia (BG >
200 mg/dl) 
0.6 ± 1.6 5.0 ± 4.7 < 0.0001
Duration of insulin infusion (days) 2.1 ± 6.6 8.7 ± 12.7 0.832
Insulin infusion rate (unit/hr/kg) 0.4 ± 1.3 2.4 ± 2.7 < 0.0001
We divided the subjects into two groups according to the average blood glucose 
level during the first week of ICU care: < 140 mg/dl, normoglycemia group vs ≥
140  mg/dl,  hyperglycemia  group. 
BG,  blood  glucose;  ICU,  Intensive  care  unit;  TPN,  total  parenteral  nutrition;  EN, 
Enteral  nutrition
Table 2. TPN delivery, blood glucose concentration and insulin use in the 
normoglycemia and hyperglycemia groups
Independent Variable B SE B Beta P-value
Dextrose delivery via TPN (g/kg/day) 7.2 3.0 0.29 0.021
Constant 138.6 3.0 < 0.0001
I n d e p e n d e n t  v a r i a b l e s :  A g e ,  A P A C H E  Ⅱ  ( A c u t e  P h y s i o l o g y  a n d  C h r o nic  Health 
Evaluation  Ⅱ)  score,  Baseline  blood  glucose  concentration,  dextrose  delivery  via 
TPN
Table 3. Stepwise multiple regression analysis Comparison between the two groups according to blood glucose 
levels
Fifty-nine patients (67%) were classified as the hyperglycemia 
group. There was no difference in patient characteristics between 
the groups (Table 1). Age, APACHE Ⅱ  score, duration of 
mechanical ventilation and length of ICU stay were identical 
between the two groups. Mortality in the ICU was significantly 
higher in the hyperglycemia group (42.4% vs 13.8%, P= 0.008), 
while the incidence of complications was not different between 
the two groups.
Patterns of PN order and BG levels are presented in Table 
2. The time to initiation of TPN from ICU admission, duration 
of TPN use and overfeeding in the process of transitioning from 
TPN to EN were not significantly different between the two 
groups. Baseline glucose level, average BG concentration and 
frequency of hyperglycemia during the first week of ICU stay 
were significantly higher in the hyperglycemia group than in the 
normoglycemia group. While the duration of insulin infusion 
failed to show a statistically significant difference between the 
two groups, the average insulin infusion rate was significantly 
higher in the hyperglycemia group than in the normoglycemia 
group. (2.4 ± 2.7 units/hr/kg vs 0.4 ± 1.3 units/hr/kg, P< 0.0001) 
More dextrose was provided via TPN and other IV fluids in 
the hyperglycemia group (2.6 ± 1.4 g/kg/day vs 1.8 ± 1.3 g/kg/ 
day, P = 0.013) (Fig. 1). Carbohydrate delivery via the enteral 
route was significantly less in the hyperglycemia group than in 
the normoglycemia group, and total carbohydrate delivery was 
not different between the two groups. 
We conducted multiple linear regression analysis including 
age, APACHE Ⅱ score, baseline BG concentration and dextrose 
delivery via the parenteral route. Dextrose delivery from PN was 
found to be the only significant variable (Table 3). When dextrose 
delivery from TPN was increased by 1 g, BG concentration 
increased by 7.2 mg/dl (CI 1.29-13.31, P = 0.021). 
Discussion
We demonstrated that dextrose delivery from TPN and 
mortality were significantly higher in the hyperglycemia group 
during the 1
st week of ICU care, which was similar to the results 
of previous studies [8,9]. Lin et al. [8] demonstrated that 
mortality was 2-5 times higher and the incidence of complications 
was 4-5.5 times higher in the group with BG ≥137 mg/dl than 
in the group with BG < 114 mg/dl. Cheung et al. [5] reported 
that mortality in patients with BG ≥ 9.1 mmol/l (164 mg/dl) 
was 11 times higher than that of patients with BG < 6.9 mmol/l 
(124 mg/dl), and this difference was more obvious in individuals 
without pre-diagnosed diabetes mellitus. Meanwhile, Pasquel et 
al. [9] reported that blood glucose before and within 24 h of 
starting TPN was associated with an increased risk of complica-
tions and mortality. 
The target BG level for critically ill patients has been a 
controversial issue. Van den Berghe et al. [10,11] reported that 
intensive insulin therapy aiming for a BG level of less than 110 
mg/dl could reduce the incidence of complications and mortality 
in surgical and medical intensive care units. Another multicenter 
study [12] suggested that BG ≤ 140-150 mg/dl was the target 
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hypoglycemia. However, these studies did not consider delivery 
of dextrose (or carbohydrate) from PN or EN, which could be 
closely related to the development of hyperglycemia. Our data 
showed that the amount of dextrose delivered via TPN was 
significantly higher in the hyperglycemia group, and the amount 
of dextrose from TPN was a significant variable upon multiple 
linear regression analysis. It was recommended that no more than 
4 mg/kg/min of dextrose from PN be provided to the critically 
ill and 7 mg/kg/min for stable patients in order to prevent 
complications including hyperglycemia [13]. For diabetes mellitus 
(DM) patients, TPN should be initiated with dextrose of ≤
100-150 g/day and then increased to the goal rate after BG level 
is maintained within the target range [14]. Our subjects had not 
been diagnosed with DM before ICU admission, and the average 
amount of dextrose from TPN in the hyperglycemia group was 
2.6 ± 1.4 g/kg, which was within the recommended range. 
However, the amount of carbohydrates from EN was smaller in 
the hyperglycemia group than in the normoglycemia group, and 
the total amount of carbohydrates from EN and TPN did not 
differ between the two groups. EN carbohydrate delivery was 
not found to be associated with BG levels upon multiple 
regression analysis when considering EN carbohydrate delivery 
instead of PN dextrose. 
In this study, TPN was initiated within the first week of ICU 
care in 75 patients (85.2%), and 61 (81.3%) of these were 
provided with EN within three days, suggesting that many 
patients were prescribed TPN despite their ability to tolerate EN. 
One study reported that 30-40% of the patients who were 
administered TPN were inadequately ordered [15], and that 
inadequate use of TPN could be reduced to less than 10% by 
implementing proper guidelines, supervision and nutrition 
support team activity [16]. Therefore, complications associated 
with hyperglycemia might be reduced by implementing guidelines 
for proper PN initiation and monitoring. The proper timing for 
TPN initiation has not yet been decided. Current clinical 
guidelines for nutritional support in critically ill patients differ 
substantially across the continents [3,4], indicating the need for 
more studies. Our results support the ASPEN guidelines, which 
recommend early initiation of EN and delayed initiation of TPN 
for critically ill patients who are well-nourished at baseline. 
We expected higher incidences of complications in the 
hyperglycemia group, but complication incidence was similar 
between the two groups. A higher rate of bloodstream infection 
was reported in the TPN treated patients [17]. A study on 
hematopoietic stem cell transplant recipients reported that a 
significantly greater number of TPN recipients required transfusion 
and delayed engraftment time [18]. Prospective studies will be 
needed to further elucidate the complications of TPN. 
This study had some limitations. First, we compared the 
clinical outcomes on the basis of the BG concentration during 
the first week of ICU care. Although the mortality of the 
hyperglycemia group was higher than that of the normoglycemia 
group, we could not exclude the possibility of aggravation of 
the medical condition after the first week of ICU stay. However, 
Pasquel et al. [9] demonstrated that BG level prior to and within 
24 h of PN initiation was associated with clinical outcomes rather 
than the average BG level during TPN therapy, emphasizing the 
importance of initial control of the BG level. It may be possible 
to overcome this limitation if we prospectively monitor the 
subjects’ daily SOFA (sequential organ failure assessment) 
scores, which are used to track patients’ status during their stay 
in an ICU [19]. Second, we considered the effect of carbohydrate 
on the BG level. Protein and fat, especially monounsaturated fatty 
acids and short chain fatty acids, can affect insulin sensitivity 
and/or gluconeogenesis [20-22]. Provision of protein and fat via 
TPN or EN might contribute to reducing the incidence of 
hyperglycemia by compromising the catabolic effect of body 
protein and body fat as the response to stress, which precluded 
further investigation.
In conclusion, our study showed that the amount of dextrose 
delivered via TPN might be associated with the development of 
hyperglycemia and poor clinical outcomes in critically ill patients 
without a history of diabetes mellitus and should be adapted 
carefully to maintain blood glucose within the target range.
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